Florian Rieder, MD
Gastroenterology · Cleveland, OHNPI 1013233600
Payments from drug & device makers
Across 358 payments — averaging $24,227 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4.9M
- AstraZeneca$887K
- AbbVie$548K
- Bristol Myers Squibb$493K
- Boehringer Ingelheim$483K
- Ferring Pharmaceuticals Inc.$481K
- plus $880K from 18 others
Across 1 payment — averaging $3850.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$4K
What the payments were for
- Consulting fees$333,66684%
- Speaking & faculty fees$25,7717%
- Travel & lodging$30,2588%
- Food & beverage$5,8801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 40 | $4,900,213 |
| AstraZeneca | 3 | $887,238 |
| AbbVie(2 entities) | 111 | $548,404 |
| Bristol Myers Squibb | 11 | $493,174 |
| Boehringer Ingelheim | 26 | $483,387 |
| Ferring Pharmaceuticals Inc. | 1 | $481,000 |
| Gilead | 23 | $389,762 |
| UCB SA | 2 | $214,822 |
| Merck | 67 | $73,846 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $58,207 |
| Boehringer Ingelheim International GmbH | 18 | $44,481 |
| Genentech, Inc. | 9 | $25,771 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $20,125 |
| Astrazeneca UK Limited | 3 | $14,587 |
| E.r. Squibb & Sons, L.L.C. | 11 | $12,343 |
| GSK | 4 | $8,450 |
| Sanofi-aventis U.S. LLC | 6 | $8,286 |
| Techlab, Inc. | 2 | $3,900 |
| Ferring Pharmaceuticals AS | 1 | $2,472 |
| F. Hoffmann-la Roche AG | 2 | $1,066 |
| Eli Lilly | 1 | $900 |
| Samsung Bioepis Co., Ltd. | 1 | $550 |
| Surmodics, Inc. | 1 | $225 |
| Sanofi US Services Inc. | 2 | $166 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,673,375 in reported general payments places this provider in the 95th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 22 | $577,134 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Cleveland
- Pierre GholamCleveland$1.9M
- Benjamin CohenCleveland$1.9M
- Bret LashnerCleveland$628K
- Jeffry KatzCleveland$602K
- Samita GargCleveland$470K
- Stanley CohenCleveland$382K
- Katherine FalloonCleveland$339K
- Mazen IssaCleveland$329K
- Taha QaziCleveland$307K
- Bo ShenCleveland$264K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.